urothelial cancer
Showing NaN - NaN of 11
Urothelial Cancer Trial in Worldwide (Nivolumab, Ipilimumab, Gemcitabine)
Recruiting
- Urothelial Cancer
- Nivolumab
- +4 more
-
Birmingham, Alabama
- +196 more
Jan 17, 2023
Advanced Malignancies, NSCLC, Ovarian Cancer Trial in Worldwide (Avelumab, Lorlatanib, Talazoparib)
Recruiting
- Advanced Malignancies
- +4 more
- Avelumab
- +7 more
-
Fayetteville, Arkansas
- +61 more
Jan 10, 2023
Urothelial Cancer Trial in Worldwide (MEDI4736 (Durvalumab), Tremelimumab, Cisplatin)
Active, not recruiting
- Urothelial Cancer
- MEDI4736 (Durvalumab)
- +4 more
-
Los Angeles, California
- +221 more
Nov 2, 2022
Urothelial Cancer Trial in Worldwide (Avelumab, Best Supportive Care, Following the planned interim analysis for this study:
Active, not recruiting
- Urothelial Cancer
- Avelumab
- +2 more
-
Aurora, Colorado
- +370 more
Oct 24, 2022
NSCLC, Urothelial Cancer Trial in Worldwide (Avelumab 800 mg in combination with pemetrexed / carboplatin, Avelumab 800 mg in
Active, not recruiting
- Non-small Cell Lung Cancer
- Urothelial Cancer
- Avelumab 800 mg in combination with pemetrexed / carboplatin
- +3 more
-
Tucson, Arizona
- +45 more
Oct 13, 2022
Urothelial Cancer Trial in Australia, Canada (Nab-Paclitaxel, Paclitaxel)
Completed
- Urothelial Cancer
-
Douglas, Queensland, Australia
- +36 more
Oct 28, 2020